Neogen Corp (NEOG) Stock Analysis and Metrics

Sector: Healthcare Industry: Medical Devices CIK: 0000711377

Market Cap 1.94 Bn

P/E -3.18

P/S 2.23

Div. Yield 0.00

ROIC (Qtr) 0.00

Total Debt (Qtr) 793.30 Mn

Revenue Growth (1y) (Qtr) -4.43

Add ratio to table...

About

Neogen Corporation develops manufactures and markets a diverse line of products and services dedicated to food and animal safety. The company’s mission is to be the leading company in fueling a brighter future for global food safety. Neogen operates worldwide with facilities in the United States Europe Brazil Australia China and Canada. The company exports its products to more than 100 countries through a network of distributors and direct sales teams. Neogen generates revenue from the sale of diagnostic test kits culture media veterinary instruments...

Neogen Corporation develops manufactures and markets a diverse line of products and services dedicated to food and animal safety. The company’s mission is to be the leading company in fueling a brighter future for global food safety. Neogen operates worldwide with facilities in the United States Europe Brazil Australia China and Canada. The company exports its products to more than 100 countries through a network of distributors and direct sales teams.

Neogen generates revenue from the sale of diagnostic test kits culture media veterinary instruments pharmaceuticals vaccines diagnostic services genomics testing and software solutions. The Food Safety segment contributes the majority of sales while the Animal Safety segment provides the remainder. In fiscal year 2025 the Food Safety segment accounted for 71.3% of total revenue and the Animal Safety segment accounted for 28.7%. The company also incurs royalty expenses for licensed technology used in certain test kits with rates typically ranging from two to ten percent of sales on those products.

The company operates through the following segments: Food Safety and Animal Safety.

• Food Safety: This segment develops manufactures and markets diagnostic test kits for pathogen toxin allergen detection culture media and related software for food and feed producers processors and regulatory agencies to ensure safety quality and hygiene.

• Animal Safety: This segment develops manufactures and markets veterinary instruments pharmaceuticals vaccines diagnostic products rodent and insect control cleaners disinfectants and genomics testing services for livestock producers veterinarians and companion animal owners worldwide.

Neogen holds a strong position in the food and animal safety markets because of its broad product line and focus on ease of use speed accuracy and customer service. The company competes with many specialized firms and divisions of large multinational corporations but differentiates itself through low cost manufacturing an extensive global distribution network and continuous innovation. Investment in research and development supports the launch of new tests and technologies that keep pace with evolving regulatory and market demands. While no single competitor dominates the entire field Neogen’s combination of product depth and service quality provides a durable advantage.

Neogen serves food and beverage processors meat and poultry producers dairy operations fruit and vegetable growers seafood handlers and bakery manufacturers. In the animal health arena the company sells to veterinary clinics livestock producers pet owners horse farms and research institutions. Government agencies such as the USDA and FDA also use Neogen’s diagnostic tools for monitoring and enforcement. Additionally the company supplies genomics services to breed associations universities and commercial laboratories worldwide.

Investment thesis

Bull case

Neogen’s newly appointed leadership team brings deep experience from leading diagnostics and life‑science companies, which is likely to accelerate the execution of the company’s transformation roadmap. The CEO’s focus on weekly commercial reviews and a data‑driven sales culture has already started to lift forecasting accuracy, as evidenced by the quarterly lift in core revenue and the positive adjustment to full‑year guidance. By embedding disciplined sales planning and resource allocation, the organization is positioning itself to capture additional customer stickiness through solutions‑based selling, a strategy that should translate into higher mix and margin expansion in the medium term. The tangible progress in improving sample collection operations and the expected profitability of that product line will further reinforce top‑line growth.
The company’s cost‑saving initiatives, totaling an estimated $20 million in annualized savings from the second quarter, have already contributed to a nearly 500‑basis‑point sequential improvement in adjusted EBITDA margin. These actions, coupled with a disciplined headcount reduction, provide a sustainable platform for margin expansion as production efficiencies mature across the portfolio. Management’s emphasis on operational execution and inventory optimization will likely reduce write‑offs and improve working capital performance, directly feeding into free cash flow. This fiscal discipline strengthens the balance sheet, enabling more aggressive capital allocation or debt repayment that could improve shareholder value.
The 2027 Petrifilm integration remains on schedule, with production testing having progressed without major setbacks. Demonstrated ability to manufacture all 17 SKUs indicates the company’s technical competency in scaling complex diagnostic products, which could open new revenue streams once commercialized. Given the company’s leading position in the food safety market and its broad customer base, the additional product portfolio is expected to deepen penetration and foster cross‑selling opportunities, driving higher average revenue per customer. This expansion aligns with secular growth in food safety requirements driven by regulatory tightening and consumer demand for traceability.
Neogen’s decision to divest its global genomics business, a process that is expected to complete in the fourth quarter, will simplify the operating model and free capital for debt reduction. Eliminating a lower‑margin, high‑capital‑intensity segment should improve overall gross margin and provide a clearer strategic focus on core diagnostics and safety solutions. The proceeds will likely accelerate deleveraging, improving leverage ratios and providing a cushion against macroeconomic volatility. A leaner balance sheet also offers flexibility to pursue strategic acquisitions that can accelerate growth or provide complementary capabilities.
The food safety segment continues to benefit from a high‑growth sub‑segment in indicator testing and culture media, driven largely by organic volume increases rather than price changes. The company’s market leadership in petri film and pathogen detection, coupled with sustained demand for allergens and natural toxins, positions it well to capture the growing need for rapid, reliable testing in the global food supply chain. As regulatory requirements tighten worldwide, the firm’s broad, integrated solution set will be increasingly attractive to manufacturers seeking to mitigate product‑recall risk. This trend is expected to sustain and potentially accelerate revenue growth in the coming years.

Neogen’s newly appointed leadership team brings deep experience from leading diagnostics and life‑science companies, which is likely to accelerate the execution of the company’s transformation roadmap. The CEO’s focus on weekly commercial reviews and a data‑driven sales culture has already started to lift forecasting accuracy, as evidenced by the quarterly lift in core revenue and the positive adjustment to full‑year guidance. By embedding disciplined sales planning and resource allocation, the organization is positioning itself to capture additional customer stickiness through solutions‑based selling, a strategy that should translate into higher mix and margin expansion in the medium term. The tangible progress in improving sample collection operations and the expected profitability of that product line will further reinforce top‑line growth.
The company’s cost‑saving initiatives, totaling an estimated $20 million in annualized savings from the second quarter, have already contributed to a nearly 500‑basis‑point sequential improvement in adjusted EBITDA margin. These actions, coupled with a disciplined headcount reduction, provide a sustainable platform for margin expansion as production efficiencies mature across the portfolio. Management’s emphasis on operational execution and inventory optimization will likely reduce write‑offs and improve working capital performance, directly feeding into free cash flow. This fiscal discipline strengthens the balance sheet, enabling more aggressive capital allocation or debt repayment that could improve shareholder value.
The 2027 Petrifilm integration remains on schedule, with production testing having progressed without major setbacks. Demonstrated ability to manufacture all 17 SKUs indicates the company’s technical competency in scaling complex diagnostic products, which could open new revenue streams once commercialized. Given the company’s leading position in the food safety market and its broad customer base, the additional product portfolio is expected to deepen penetration and foster cross‑selling opportunities, driving higher average revenue per customer. This expansion aligns with secular growth in food safety requirements driven by regulatory tightening and consumer demand for traceability.
Neogen’s decision to divest its global genomics business, a process that is expected to complete in the fourth quarter, will simplify the operating model and free capital for debt reduction. Eliminating a lower‑margin, high‑capital‑intensity segment should improve overall gross margin and provide a clearer strategic focus on core diagnostics and safety solutions. The proceeds will likely accelerate deleveraging, improving leverage ratios and providing a cushion against macroeconomic volatility. A leaner balance sheet also offers flexibility to pursue strategic acquisitions that can accelerate growth or provide complementary capabilities.
The food safety segment continues to benefit from a high‑growth sub‑segment in indicator testing and culture media, driven largely by organic volume increases rather than price changes. The company’s market leadership in petri film and pathogen detection, coupled with sustained demand for allergens and natural toxins, positions it well to capture the growing need for rapid, reliable testing in the global food supply chain. As regulatory requirements tighten worldwide, the firm’s broad, integrated solution set will be increasingly attractive to manufacturers seeking to mitigate product‑recall risk. This trend is expected to sustain and potentially accelerate revenue growth in the coming years.

Bear case

The voluntary recall of the Vet HYCOAT® product line, triggered by microbial contamination in certain lots, introduces a significant reputational and financial risk. Although the company has not yet reported adverse events associated with the labeled use, the potential for infection in animals, especially during intraarticular injections, raises liability concerns that could result in costly product liability claims and additional regulatory scrutiny. The recall process, involving nationwide distribution and coordination with the FDA, is likely to impose immediate cash outlays for returns, replacements, and potential legal costs, thereby compressing short‑term profitability.
The recall also underscores a broader issue of product quality and supply chain oversight. Management’s acknowledgment that the contaminated vials were manufactured by a third‑party supplier points to a vulnerability in the company’s vendor management and quality assurance processes. If similar lapses recur across other product lines, the company could face a cascade of recalls, further eroding customer confidence and potentially leading to lost market share to competitors with stricter quality controls.
While the company reports improvements in sample collection profitability, the segment remains a “gateway product” with historically lower margin potential compared to other product lines. Management’s candid admission that the product may never be as profitable as other portfolio items signals an inherent limitation in the company’s revenue mix. Persistent low‑margin contributions could constrain overall profitability, especially if the company needs to sustain large volumes to compensate for higher‑margin segments that are subject to market cyclicality.
Animal safety revenues, while flat core growth in the quarter, are subject to a multiyear downward trend in U.S. production herds, a key driver of demand for insecticide and veterinary instrument products. The company’s cautious approach to guidance reflects uncertainty in this segment’s recovery, and a continued decline could erode the diversified revenue base. Even though the Latin American region shows growth, the company remains heavily exposed to the U.S. market where herd sizes have fallen to record lows, limiting upside potential in a critical growth region.
The company’s inventory write‑offs in the quarter signal potential issues with inventory management and demand forecasting. Elevated write‑offs can be a temporary measure but may also indicate overproduction or misaligned supply chain dynamics that could persist. If inventory levels remain high, the company will face ongoing working‑capital pressure, which can dilute free cash flow and strain cash conversion cycles.

The voluntary recall of the Vet HYCOAT® product line, triggered by microbial contamination in certain lots, introduces a significant reputational and financial risk. Although the company has not yet reported adverse events associated with the labeled use, the potential for infection in animals, especially during intraarticular injections, raises liability concerns that could result in costly product liability claims and additional regulatory scrutiny. The recall process, involving nationwide distribution and coordination with the FDA, is likely to impose immediate cash outlays for returns, replacements, and potential legal costs, thereby compressing short‑term profitability.
The recall also underscores a broader issue of product quality and supply chain oversight. Management’s acknowledgment that the contaminated vials were manufactured by a third‑party supplier points to a vulnerability in the company’s vendor management and quality assurance processes. If similar lapses recur across other product lines, the company could face a cascade of recalls, further eroding customer confidence and potentially leading to lost market share to competitors with stricter quality controls.
While the company reports improvements in sample collection profitability, the segment remains a “gateway product” with historically lower margin potential compared to other product lines. Management’s candid admission that the product may never be as profitable as other portfolio items signals an inherent limitation in the company’s revenue mix. Persistent low‑margin contributions could constrain overall profitability, especially if the company needs to sustain large volumes to compensate for higher‑margin segments that are subject to market cyclicality.
Animal safety revenues, while flat core growth in the quarter, are subject to a multiyear downward trend in U.S. production herds, a key driver of demand for insecticide and veterinary instrument products. The company’s cautious approach to guidance reflects uncertainty in this segment’s recovery, and a continued decline could erode the diversified revenue base. Even though the Latin American region shows growth, the company remains heavily exposed to the U.S. market where herd sizes have fallen to record lows, limiting upside potential in a critical growth region.
The company’s inventory write‑offs in the quarter signal potential issues with inventory management and demand forecasting. Elevated write‑offs can be a temporary measure but may also indicate overproduction or misaligned supply chain dynamics that could persist. If inventory levels remain high, the company will face ongoing working‑capital pressure, which can dilute free cash flow and strain cash conversion cycles.

Product and Service Breakdown of Revenue (2025)

Peer comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	152.82 Bn	24.43	3.39	34.05 Bn
2	SYK	Stryker Corp	115.07 Bn	34.42	4.55	14.72 Bn
3	MDT	Medtronic plc	95.25 Bn	20.64	2.68	28.07 Bn
4	BSX	Boston Scientific Corp	71.38 Bn	19.95	3.46	11.03 Bn
5	EW	Edwards Lifesciences Corp	51.08 Bn	47.93	8.10	0.60 Bn
6	PHG	Koninklijke Philips Nv	29.38 Bn	13,009.40	1.46	8.07 Bn
7	DXCM	Dexcom Inc	28.84 Bn	31.21	5.99	-
8	GEHC	GE HealthCare Technologies Inc.	28.56 Bn	14.98	1.36	10.13 Bn

Research Tools

Developers

Neogen Corp (NASDAQ: NEOG)

About

Investment thesis

Bull case

Bear case

Product and Service Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

Peer comparison

Research Tools

Developers

Neogen Corp (NASDAQ: NEOG)

About

Investment thesis

Bull case

Bear case

Product and Service Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

Peer comparison

Create an account

Sign In

Reset Password